Abstracts tagged "Biomarkers"

Abstract Number: 0271 • ACR Convergence 2024
Intercritical Gout Represents a Systemic Inflammatory State
Tanner Ourada¹, Austin Wheeler², Michael Duryee², Bryant England², Richard Reynolds³, James O'Dell², Jeff Newcomb², Michael Pillinger⁴, Robert Terkeltaub⁵, Ryan Ferguson⁶, Mary Brophy⁶, Tony Merriman⁷ and Ted Mikuls², ¹University of Nebraska-Medical Center: College of Medicine, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Alabama at Birmingham, Birmingham, AL, ⁴New York University Grossman School of Medicine, New York,, NY, ⁵Retired, San Diego, CA, ⁶Veterans Affairs, Boston, MA, ⁷University of Alabama at Birmingham, Homewood, AL
Background/Purpose: The presence of systemic inflammation during gout flares is well characterized. While initial research suggests inflammation persists in intercritical gout, these reports have come…
Abstract Number: 0470 • ACR Convergence 2024
New Approach for Early and Accurate Diagnosis of Rheumatoid Arthritis-related Interstitial Lung Disease: Matrix Metalloproteinases 7 and 9 as Novel Blood Biomarkers
Veronica Pulito-Cueto¹, Belén Atienza-Mateo², gonzalo Ocejo-Viñals³, Victor M. Mora-Cuesta⁴, David Iturbe-Fernández⁴, Joao Carlos Batista-Liz¹, María Sebastián Mora-Gil⁵, Mónica Renuncio-García⁶, Elena González López³, José M. Cifrián⁷, Ricardo Blanco-Alonso⁸ and Raquel Lopez-mejias¹, ¹IDIVAL, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Department of Immunology, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain, ⁴Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Pneumology, Marqués de Valdecilla University Hospital (HUMV), Santander, ⁵Immunopathology Group, Valdecilla Research Institute (IDIVAL) and Department of Rheumatology, Marqués de Valdecilla University Hospital (HUMV), Santander, ⁶Division of Immunology, Hospital Universitario Marqués de Valdecilla, Immunopathology Group, IDIVAL, Santander, Spain, ⁷Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. Immunopathology group, IDIVAL, Santander, ⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is one of the main causes of death in rheumatoid arthritis (RA) patients [1]. Early diagnosis of RA-ILD+ is critical…
Abstract Number: 0610 • ACR Convergence 2024
Clinical Evaluation on IFI44L Gene Methylation Detection for Diagnosis of Systemic Lupus Erythematosus by Methylation Sensitive High Resolution Melting (MS-HRM)
Xiaoping hong and liancheng lin, The Second Clinical Medical College of Jinan University, Shenzhen, China (People's Republic)
Background/Purpose: To evaluate the clinical effectiveness of IFI44L gene methylation detection for the diagnosis of Systemic Lupus Erythematosus (SLE) by MS-HRM, to determine the relative…
Abstract Number: 0725 • ACR Convergence 2024
Serum Glial Fibrillary Acidic Protein Could Assess Cross-sectional Vasculitis Activity by Reflecting Renal Involvement in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Lucy Eunju Lee¹, Taejun Yoon², Yong-Beom Park² and Sang-Won Lee², ¹Yonsei University, Seoul, South Korea, ²Yonsei University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Glial fibrillary acidic protein (GFAP), an intermediate filament protein produced by astrocytes in the CNS, has been identified as a biomarker for disease activity…
Abstract Number: 0863 • ACR Convergence 2024
The Development of Future Radiographic Knee Osteoarthritis Can Be Predicted by Peripheral Blood Epigenetic Models
Cindy Miranda¹, Nicholas Hannebutt², Gabby dyson³, Montana Barrett⁴, Aleksander Szymczak³ and Matlock Jeffries³, ¹Oklahoma Medical Research Foundation, Yukon, OK, ²Oklahoma Medical Research Foundation, Spencer, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴University of Oklahoma, Cement, OK
Background/Purpose: Knee osteoarthritis (OA) is a heterogeneous disease characterized by a variety of clinical and molecular phenotypes. However, we do not yet have robust biomarkers…
Abstract Number: 1110 • ACR Convergence 2024
Microvascular Abnormalities in COVID-19 Survivors and LONG COVID
Rosanna Campitiello¹, Emanuele Gotelli², Elvis Hysa³, Carmen Pizzorni⁴, Alberto Sulli⁵, Sabrina Paolino⁶, Alessandro Pinelli⁷, Tamara Vojinovic², vanessa smith⁸ and Maurizio Cutolo², ¹Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genova, Liguria, Italy, ²Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genova, Italy, ³Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genoa, Italy, ⁴Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ⁵Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Genova, Italy, ⁶Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Specialties (Di.M.I.), University of Genova; IRCCS Ospedale Policlinico San Martino, Genova, Liguria, Italy, ⁷Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Specialties (Di.M.I.), University of Genova; IRCCS Ospedale Policlinico San Martino, Genova, ⁸Ghent University Hospital, Gent, Belgium
Background/Purpose: Coronavirus disease 2019 (COVID-19) is an infective disease known to cause mainly respiratory symptoms along with a wide range of systemic manifestations [1]. Long…
Abstract Number: 1349 • ACR Convergence 2024
Two Composite Cytokine Scores Predict Flare and Drug-free Remission in Patients with Rheumatoid Arthritis
Jasmine Sim¹, Nandhini Ramamoorthi², Fiona Rayner³, Abbie Degnan¹, Imogen Wilson¹, Julie Diboll¹, Anna Guttman⁴, Andrew Melville⁵, Nisha Rathore², Stefan Siebert⁵, Iain McInnes⁶, Carl Goodyear⁵, Catharien Hilkens¹, Andrew Filer⁷, Karim Raza⁷, Christopher Buckley⁸, Arthur Pratt¹, James Wason⁹, Amy Anderson¹, Michael Townsend², Kenneth Baker¹ and John Isaacs¹, ¹Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Genentech, South San Francisco, CA, ³Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, ⁴Genentech, South San Franscisco, CA, ⁵School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁶University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁷Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, ⁸Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ⁹Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Recent studies show that half of patients with RA remission can stop conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) therapy to achieve drug-free remission (DFR),…
Abstract Number: 1607 • ACR Convergence 2024
Low Concentrations of Anti-C5a Complement Receptor Antibodies Are Associated with Relapse in Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Sebastian Klapa¹, Sabrina Arnold², Antje Müller², Andreas Koch³, Anja Staehle⁴, Wataru Kähler³, Harry Heidecke⁵, Gabriela Riemekasten² and Peter Lamprecht², ¹University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, ²University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, ³Christian-Albrechts-University Kiel, Institute of Experimental Medicine, Kiel, Germany, ⁴University of Lübeck, Department of Rheumatology and Immunology, Lübeck, Germany, ⁵CellTrend GmbH, Luckenwalde, Germany
Background/Purpose: Complement activation has been shown to play an important role in the pathogenesis of the two major anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) variants,…
Abstract Number: 1815 • ACR Convergence 2024
Leveraging Novel Systemic Sclerosis Disease Signatures to Build a Humanized Drug Discovery Funnel
Lauren Reinke-Breen¹, Laura Leys¹, Sunhwa Kim², Lauren Olson¹, Anastasia Marinopoulos¹, Chris Butler¹, Jennifer Van Camp¹ and Lisa Hazelwood¹, ¹AbbVie, North Chicago, IL, ²AbbVie, South San Francisco, CA
Background/Purpose: Systemic sclerosis (SSc) is a chronic, progressive autoimmune disorder with significant morbidity and mortality. The lack of effective therapies for SSc is, in part,…
Abstract Number: 2145 • ACR Convergence 2024
Study of Bone Metabolism in Patients Diagnosed with Osteogenesis Imperfecta.
Daniel Ramos Castro¹, SAMUEL LEAL², Elena Grau García³, JOSE ELOY OLLER RODRIGUEZ⁴, José Ivorra-Cortés⁵, Carmen Riesco Barcena⁶, Anderson Huaylla Quispe⁷, Pablo Muñoz Martínez⁸, Laura Mas Sánchez⁹, Alba Torrat noves¹⁰, Belén Villanueva Mañés¹¹, Iago Alcántara Álvarez¹², Andrés Pérez Hurtado¹, Miguel Simeo Vinaixa¹¹ and Jose A Román-Ivorra¹³, ¹Rheumatology Department. HUP La Fe, Valencia, Spain, ²Hospital La Fe, Valencia, Spain, ³HUP La Fe, Valencia, Spain, ⁴HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE, VALENCIA, Spain, ⁵Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, ⁶Hospital Universitario i Politecnic La Fe (Valencia-Spain), Valéncia, Spain, ⁷Medicina, Valéncia, Spain, ⁸Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ⁹Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ¹⁰Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ¹¹Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ¹²Hospital Universitari i Politècnic La Fe, Valéncia, Comunidad Valenciana, Spain, ¹³Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Osteogenesis imperfecta (OI) is a hereditary connective tissue disorder (90% autosomal dominant) characterized by a disruption in type 1 collagen or proteins associated with…
Abstract Number: 2390 • ACR Convergence 2024
Anti-Sm Antibody Titers Vary During SLE Disease Course
Faye Megaris¹, Emily Wu² and Kyriakos Kirou³, ¹CUNY School of Medicine, Astoria, NY, ²Hospital for Special Surgery, Rochester, NY, ³Hospital for Special Surgery, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by positive antibodies to dsDNA and/or Sm which have high specificity for the disease. While anti-dsDNA titers are…
Abstract Number: 2578 • ACR Convergence 2024
Safety, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptor 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase1/2 Study in Systemic Lupus Erythematosus
Yoshiya Tanaka¹, Atsushi Kumanogoh², Tatsuya Atsumi³, Tomonori Ishii⁴, Fumitoshi Tago⁵, Mari Aoki⁵, Shintaro Yamamuro⁵, Keisuke Sakayori⁵, Kentaro Takahashi⁵ and Shizuo Akira⁶, ¹Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ²Osaka University, Osaka, Japan, ³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ⁴Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, sendai, Japan, ⁵Eisai Company, Ltd., Tokyo, Japan, ⁶Osaka University Immunology Frontier Research Center, Osaka, Japan
Background/Purpose: There is strong evidence for the relationship between Toll-like receptor (TLR)7/8 and systemic lupus erythematosus (SLE) pathophysiology. Dual inhibition of TLR7/8 will modulate innate…
Abstract Number: 0316 • ACR Convergence 2024
Development and Evaluation of the Adult-onset Still’s Disease Activity Index Based on Whole RNA-seq Analysis: A Novel Approach Independent of Tocilizumab Treatment
Mayu Magi¹, Hiroto Yoshida¹, Hiroya Tamai², Kotaro Matsumoto², Keiko Yoshimoto², Yoshihiro Matsumoto¹, Tetsuhiro Soeda¹ and Yuko Kaneko², ¹Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan, ²Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Tocilizumab (TCZ), an anti-IL-6 receptor antibody, has been shown to be effective in the treatment of adult-onset Still's disease (AOSD), a systemic inflammatory disease.…
Abstract Number: 0478 • ACR Convergence 2024
Skin Sodium in Patients with Rheumatoid Arthritis: Association with Blood Pressure and Disease Activity
Carolina Ramirez, Annette Oeser, Rachelle Crescenzi, C. Michael Stein and Michelle Ormseth, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Sodium is stored in tissues such as the skin where it may contribute to development and progression of autoimmune diseases and hypertension through activation…
Abstract Number: 0630 • ACR Convergence 2024
Lupus Lymphocyte Activation Score of Pathologic T and B Cell Phenotypes Increased in Patients at Risk of Systemic Lupus Erythematosus
Alice Horisberger¹, Ifeoluwakiisi Adejorin², Julia Caldropoli³, Eilish Dillon⁴, Emily Oakes⁵, Kathryne Marks⁵, Takanori Sasaki⁶, Karen Costenbader⁷ and Deepak Rao⁴, ¹Brigham and Woman's Hospital, Harvard Medical School, Lausanne, Switzerland, ²Brigham and Woman's Hospital, Harvard Medical School, Boston, MA, ³Brigham and Woman's Hospital, Harvard Medical School, Boston, MA, Switzerland, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Brookline, MA, ⁷Brigham and Women's Hospital/ Harvard Medical School, Boston, MA
Background/Purpose: In systemic lupus erythematosus (SLE), loss of self-tolerance and pathologic T and B cell interactions lead to autoantibodies against nuclear antigens (ANA) production. In…

« Previous Page
1
…
4
5
6
7
8
…
96
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.